| Date | Time | Source | |
| 03/27/2024 | 7:00AM | GLOBE | Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H’24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral... More...>> |
| 02/28/2024 | 4:05PM | GLOBE | Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study Enrollment in Phase 3 SUNRISE-3 Study Has Surpassed 1,400 COVID-19 Patients in Monotherapy Population; Two Interim Analyses by Independent Data Safety Monitoring Board (DSMB) Planned for 1H’24... More...>> |
| 02/21/2024 | 7:00AM | GLOBE | Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday... More...>> |
| 01/08/2024 | 4:05PM | GLOBE | Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2 HCV Study Phase 3 SUNRISE-3 Enrollment Surpassed 650 Patients in Monotherapy Arm; First Interim Analysis by the Independent Data Safety Monitoring Board (DSMB) Expected in March 2024... More...>> |
| 01/03/2024 | 7:00AM | GLOBE | Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder... More...>> |
| 11/13/2023 | 7:00AM | GLOBE | Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
First Clinical Data for Coadministration of Bemnifosbuvir and Ruzasvir Show Combination Was Well Tolerated in a Phase 1 Study Plasma Pharmacokinetic (PK) Profiles of Bemnifosbuvir and Ruzasvir Were Not Affected by Food or Concomitant Dosing, Indicating Low Risk of Drug-Drug Interactions Bemnifosbuvir and Ruzasvir are Potent... More...>> |
| 11/08/2023 | 4:05PM | GLOBE | Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Patient enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19; first interim analysis expected 1Q24 Phase 2 bemnifosbuvir and ruzasvir combination trial for hepatitis C (HCV) advances, initial results from 60-patient lead-in cohort expected 1Q24 Conference call at 4:30 pm ET today... More...>> |
| 11/08/2023 | 7:00AM | GLOBE | Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in and... More...>> |
| 11/02/2023 | 7:00AM | GLOBE | Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced two upcoming poster presentations at The Liver Meeting 2023, the annual... More...>> |
| 11/01/2023 | 7:00AM | GLOBE | Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday... More...>> |
| 09/06/2023 | 7:00AM | GLOBE | Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in a... More...>> |
| 08/08/2023 | 4:05PM | GLOBE | Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19Phase 3 SUNRISE-3 trial protocol amended to broaden eligibility criteria for high-risk patients and adapt to current COVID-19 environmentEnrollment continues in Phase 2 trial evaluating combination of bemnifosbuvir and... More...>> |
| 08/01/2023 | 7:00AM | GLOBE | Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday... More...>> |
| 06/15/2023 | 7:00AM | GLOBE | Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination
BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the dosing of the first patient in the Phase 2 bemnifosbuvir and... More...>> |
| 06/05/2023 | 4:20PM | GLOBE | Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder... More...>> |
| 05/30/2023 | 7:00AM | GLOBE | Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that its Board of Directors unanimously rejected the unsolicited... More...>> |
| 05/23/2023 | 4:05PM | GLOBE | Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding common shares of Atea for $5.75 per share in cash, plus a contingent value right (“CVR”... More...>> |
| 05/08/2023 | 4:05PM | GLOBE | Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; execution of global geographic footprint Phase 2 trial evaluating combination of bemnifosbuvir and ruzasvir for treatment of HCV on track for first patient dosed 2Q23; initial results expected in... More...>> |
| 05/01/2023 | 4:05PM | GLOBE | Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Monday... More...>> |
| 04/25/2023 | 7:00AM | GLOBE | Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the United States Food and Drug Administration (FDA) has granted... More...>> |